Adherence to inhaled therapy, mortality and hospital admission in COPD

Background: Little is known about adherence to inhaled medication in chronic obstructive pulmonary disease (COPD) and the impact on mortality and morbidity. Methods: Data on drug adherence from a randomised double-blind trial comparing inhaled salmeterol 50 μg + fluticasone propionate 500 μg twice daily with placebo and each drug individually in 6112 patients with moderate to severe COPD over 3 years in the TORCH study were used. All-cause mortality and exacerbations leading to hospital admission were primary and secondary end points. The study of adherence was not specified a priori as an ancillary study. Results: Of the 4880 patients (79.8%) with good adherence defined as >80% use of study medication, 11.3% died compared with 26.4% of the 1232 patients (20.2%) with poor adherence. The annual rates of hospital admission for exacerbations were 0.15 and 0.27, respectively. The association between adherence and mortality remained unchanged and statistically significant after adjusting for other factors related to prognosis (hazard ratio 0.40 (95% CI 0.35 to 0.46), p<0.001). The association was even stronger when analysing on-treatment deaths only. Similarly, the association between adherence and hospital admission remained unchanged and significant in a multivariate analysis (rate ratio 0.58 (95% CI 0.44 to 0.73, p<0.001). The association between increased adherence and improved mortality and reduction in hospital admission was independent of study treatment. The effect of treatment was more pronounced in patients with good adherence than in those with poor adherence. Conclusion: Adherence to inhaled medication is significantly associated with reduced risk of death and admission to hospital due to exacerbations in COPD. Further research is needed to understand these strong associations.

[1]  M. Hyland,et al.  Patient needs and medication styles in COPD , 2005, European Respiratory Review.

[2]  P. Jones,et al.  Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease: Thorax 2005;60:301–4 , 2005 .

[3]  C. Jenkins,et al.  The TORCH (TOwards a Revolution in COPD Health) survival study protocol , 2004, European Respiratory Journal.

[4]  K. Peters,et al.  The Handbook of Health Behavior Change , 2009 .

[5]  Lex M Bouter,et al.  Effectiveness of an education programme by a general practice assistant for asthma and COPD patients: results from a randomised controlled trial. , 2004, Patient education and counseling.

[6]  F. Gallefoss.  The effects of patient education in COPD in a 1-year follow-up randomised, controlled trial. , 2004, Patient education and counseling.

[7]  C. Sherbourne,et al.  The impact of patient adherence on health outcomes for patients with chronic disease in the medical outcomes study , 1994, Journal of Behavioral Medicine.

[8]  D. Postma,et al.  Chronic obstructive pulmonary disease. , 2002, Clinical evidence.

[9]  Ross T Tsuyuki,et al.  A meta-analysis of the association between adherence to drug therapy and mortality , 2006, BMJ : British Medical Journal.

[10]  Thierry Troosters,et al.  Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality – a systematic review , 2005, Respiratory research.

[11]  C. Jenkins,et al.  Salmeterol/Fluticasone propionate and survival in chronic obstructive pulmonary disease:the TORCH trail. , 2007 .

[12]  J. van der Palen,et al.  Effects of a comprehensive self-management programme in patients with chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[13]  F. Maltais,et al.  Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. , 2003, Archives of internal medicine.

[14]  J. Cramer,et al.  Treatment persistence and compliance with medications for chronic obstructive pulmonary disease. , 2007, Canadian respiratory journal.

[15]  P. Jones,et al.  Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease , 2005, Thorax.

[16]  P. Schnohr,et al.  Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study , 2006, Thorax.

[17]  C. Rand,et al.  Metered-dose inhaler adherence in a clinical trial. , 1992, The American review of respiratory disease.

[18]  A. Hansell,et al.  Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. , 2005, Chest.

[19]  C. Rand.  Patient adherence with COPD therapy , 2005, European Respiratory Review.

[20]  M. McDermott,et al.  Impact of medication nonadherence on coronary heart disease outcomes. A critical review. , 1997, Archives of internal medicine.

[21]  Bartolome Celli,et al.  Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.

[22]  N. Anthonisen,et al.  Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.

[23]  R. Balkrishnan,et al.  Inhaled corticosteroid use and associated outcomes in elderly patients with moderate to severe chronic pulmonary disease. , 2000, Clinical therapeutics.

[24]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[25]  J. Chan,et al.  Effectiveness of telephone counselling by a pharmacist in reducing mortality in patients receiving polypharmacy: randomised controlled trial , 2006, BMJ : British Medical Journal.

[26]  Elizabeth M. Borycki,et al.  Reduction of Hospital Utilization in Patients With Chronic Obstructive Pulmonary Disease: A Disease-Specific Self-management Intervention , 2003 .

[27]  C. Rand,et al.  Unpredictability of deception in compliance with physician-prescribed bronchodilator inhaler use in a clinical trial. , 2000, Chest.